05.01.2022 - Press Release Stockholm, Sweden, January 5, 2022 Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors .
The CentoCloud solution is a cloud-based Software as a Service (SaaS) platform that enables laboratories around the world to analyze, interpret, and report.
Press Release Stockholm, Sweden, January 3, 2022 Immunicum to Participate in Upcoming Investor and Industry Conferences in January Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical
Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it has been awarded the Health-i Award, which recognizes companies that are transforming healthcare in Germany and beyond. The Health-i Awards are sponsored by the Techniker Krankenkasse, Germany’ s.